ClinicalTrials.gg
RecruitingNCT07479862Updated Nov 13, 2026

A Study of SA030 Injection in Overweight/Obese Participants With or Without Type 2 Diabetes Mellitus (T2DM)

A Phase 1 interventional study of SA030 Injection and Matching Placebo in Obese, Overweight and T2DM (Type 2 Diabetes Mellitus), sponsored by Suzhou Siran Biotechnology Co.,Ltd.. Recruiting at 2 sites in Australia. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Suzhou Siran Biotechnology Co.,Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.
Updated Nov 13, 2026Now RecruitingEligibility revised+8 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 188 studies in Obesity with a site in Australia — 56 open to participants now, 74 under way, 34 of them phase 3. Obesity · Australia.

Planned enrollment
139th of 169
40 · median 180
Started
2026
with 40 others
Phase 1
33 of 188
15 open now
Primary completion
2028-04
later than 51 of 73 live
Registered
159th of 188
by date

Among the 188 studies in Obesity with a site in Australia, this one is the 139th largest by planned enrollment of the 169 interventional ones that give a count, is one of 41 that started in 2026, is one of 33 in phase 1, reaches primary completion later than 51 of the 73 other live ones, and was the 159th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

56 of the 188 studies in Obesity with a site in Australia are open now. Recruiting first, the newest first:

50 more — sign in →

All 56 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Obesity with a site in Australia, or all of them as a file.
02

Study summary

This is the first time the study drug, SA030, is being given to people. The main goal of this study is to find out if it is safe, how well people can tolerate it, how the body processes the drug, how the drug works, and whether it causes any immune reactions.

The study has two parts. In Part 1, people who are overweight or have obesity will receive a single dose of the drug, starting with a low dose and slowly increasing it. In Part 2, people with obesity (with or without type 2 diabetes) will receive multiple doses over time.

SA030 is being developed as a potential new treatment for people who are overweight or have obesity.

Over the last few decades, more and more people around the world have become overweight or obese, and the numbers keep rising in almost every country. From 1990 to 2021, this problem grew steadily and reached its highest point in 2021.

03

Conditions studied

  • Obese
  • Overweight
  • T2DM (Type 2 Diabetes Mellitus)

Keywords

  • ALK7
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • You must be able to understand the study and sign a written consent form.
  • Men or women aged 18 to 55 years can join
  • Overweight or obese with a (BMI) between 25-40 kg/m\^2(inclusive);
  • You should be generally healthy, The study doctor will check your medical history, vital signs, physical exam, blood and urine tests, , and abdominal. ultrasound. Minor issues are okay if the doctor thinks they are not medically important.
  • For female participants of : must be non-pregnant and non- lactating, and agree to use highly effective throughout the study period;
  • For male participants of : must agree to use highly effective contraception during the study period to ensure effective contraception for sexual partners.

Exclusion criteria

Exclusion Criteria:

  • You cannot join if you have lost or gained more than 5 percent of your body weight in the last 3 months.
  • You cannot participate if you previously had, or plan to have, weight-loss surgery or a weight-loss device during the study, except for the following procedures done more than 1 year before screening
  • Use of any over-the-counter medications, herbal supplements, or health products that may significantly affect weight or metabolism within 1 month prior to screening (e.g., orlistat, garcinia cambogia, ephedrine, etc.)
  • At screening, sitting systolic blood pressure more than of equals to 160 milli meters of mercury and/or diastolic blood pressure more than of equals to 100 mmHg, and deemed unsuitable for participation in this study by the investigator;
  • Severe psychiatric disorders or uncontrolled psychiatric conditions, including but not limited to schizophrenia, bipolar disorder, or depression, deemed unsuitable for participation in this study by the investigator;
  • If the screening shows a prolonged /QTc interval, and a repeat test confirms QTcF greater than 450 ms in males or greater than 470 ms in females, the participant will be excluded
  • Suffering from severe diseases, including but not limited to disorders of the nervous system, cardiovascular system, hematopoietic and lymphatic system, immune system, digestive system, urinary system, respiratory system, endocrine system, and history of , which the investigator judges may compromise safety or influence study results;
  • Co-infection with virus (HBV), virus (HCV), (HIV), or syphilis; or prior diagnosis of hepatitis A, D, or E without resolution;
  • Individuals who received a vaccine or within 1 month prior to dosing, or who plan to receive a vaccine during the trial period; Major surgery within 6 months prior to screening, or planned surgery during the study period;
  • Severe infection or trauma within 4 weeks prior to screening;
  • Non-physiological blood loss more than or equals 200 milliliter within 1 month prior to study drug administration (including trauma, blood collection, or blood donation), or individuals planning to donate blood during the study period or within 60 days after dosing;
  • History of severe intolerance to subcutaneous injections (mild reactions such as local swelling or redness are permissible);
  • Individuals who have taken any prescription medication, herbal supplements, or over-the-counter drugs within 14 days prior to study drug administration;
  • Participation in other drug clinical trials within 3 months of this study's treatment initiation, or within 5 half-lives of other drug exposure, or participation in siRNA or antisense oligonucleotide drug clinical trials within 6 months prior to this study's treatment initiation (participants who withdrew from the study before receiving the investigational drug may be eligible for this study);
  • Individuals who smoked more than 5 cigarettes or an equivalent amount of tobacco daily within 3 months prior to screening, or who are unable to abstain from smoking during the trial hospitalization period;
  • Weekly alcohol consumption exceeding 14 units within 3 months prior to screening (1 unit of alcohol ≈360 milli Liter beer or 45 milli Liter 40 percent alcohol spirits or 150 milli Liter wine), or those with a positive breath alcohol test on the day before dosing (breath alcohol content more than 0.0 milligram per100 mL), or those unable to abstain from alcohol during the trial hospitalization period;
  • Current or former drug users/substance abusers, or those with a positive urine drug screen on the day before dosing;
  • Other factors deemed unsuitable for trial participation by the investigator, such as potential for poor compliance.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Single dose escalation of SA030

    single dose, 5 dose levels 1,2 3, 4 \& 5

    Drug: SA030 Injection · Drug: Matching Placebo

  • Experimental
    Multiple dose escalation of SA030 in obese participants

    Multiple dose, 3 dose levels.

    Drug: SA030 Injection · Drug: Matching Placebo

  • Experimental
    Multiple dose escalation of SA030 in obese with T2DM participants

    multiple dose; 2 dose levels

    Drug: SA030 Injection · Drug: Matching Placebo

Interventions

  • DrugSA030 Injection

    Single dose, 5 dose levels; mulitple dose, 3 dose levels or 2 dose levels

  • DrugMatching Placebo

    Single dose, matching placebo

06

What researchers measure

Primary outcomes

  1. Number of participants with adverse events (AEs) and serious adverse events (SAEs)

    Time frame: Approximatly 12 months

  2. Number of participants with clinical significant laboratory abnormalities

    Time frame: Approximatly 12 months

Secondary outcomes

  1. Peak plasma concentration (Cmax)

    Pharmacokinetic parameter

    Time frame: Pre-dose, multiple timepoints post-dose up to D5

  2. Time to peak plasma concentration (Tmax)

    Pharmacokinetic parameter

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

  3. Plasma concentration-time curve from time zero to the time of the last quantifiable concentration (AUC0-t)

    Pharmacokinetic parameter

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

  4. Plasma concentration-time curve from time zero extrapolated to infinity (AUC0-inf)

    Pharmacokinetic parameter

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

  5. Elimination half-life (t1/2)

    Pharmacokinetic parameter

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

  6. Terminal elimination rate constant (λz)

    Pharmacokinetic parameter:

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

  7. Apparent volume of distribution (Vd/F)

    Pharmacokinetic parameter

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

  8. Apparent clearance (CL/F)

    Pharmacokinetic parameter

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

  9. Number and percentage of participants developing immunogenicity (anti-SA030 antibodies)

    Time frame: Up to 12 months

  10. Changes in weight

    Time frame: baseline, up to 12 months

  11. Changes in BMI

    Time frame: baseline, up to 12 months

  12. Changes in waist circumference

    Time frame: baseline, up to 12 months

  13. Changes in hip circumference,

    Time frame: baseline, up to 12 months

  14. Changes in waist-to-hip ratio

    Time frame: baseline, up to 12 months

  15. Changes in body fat content

    Time frame: baseline, up to 12 months

  16. Change in hepatic fat content

    Time frame: baseline, up to 12 months

  17. Changes in ALK7 expression

    Time frame: baseline, up to 12 months

  18. Change in QTcF relative to baseline and relative to placebo compared to baseline

    Time frame: Pre-dose, multiple timepoints post-dose up to Day 5

07

Study locations

2 of 2 sites recruiting
  • Nucleus Network
    Brisbane, Queensland 4006, Australia
    Recruiting
    • Michael Wong, Dr · Principal investigator
  • CMAX Clinical Research Pty Ltd North Terrace
    Adelaide, 5000, Australia
    Recruiting
    • Dr. Thomas Polasek · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 338 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's planned 24 months is above that.

Counting every sponsor, half of 443 studies reached it within 11 months; a quarter within 6 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Aug 2026 → Apr 2028 and completion Mar 2027 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2026
First posted
Mar 18, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Apr 24, 2028was Aug 2026
CompletionEst.
Apr 24, 2028was Mar 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 23, 2026
Sites
1 site added. CMAX Clinical Research Pty Ltd North Terrace is now Recruiting
Show site
  • Nucleus Network · Brisbane, Australia
Oct 23, 2026
Primary completion
Aug 18, 2026→Apr 24, 2028
Oct 23, 2026
Study completion
Mar 3, 2027→Apr 24, 2028
Oct 23, 2026
Eligibility
Maximum age 55 Years→65 Years
Nov 13, 2026
Interventions
Changed Dose escalation of SA030→SA030 Injection; Matching placebo of SA030→Matching Placebo. Arm changed Dose escalation of SA030→Single dose escalation of SA030. Arms added: Multiple dose escalation of SA030 in obese participants·Multiple dose escalation of SA030 in obese with T2DM participants; arms removed: Matching placebo of SA030
across 2 updates, Oct 23, 2026 – Nov 13, 2026
Primary outcomes
2 time frame changed
What changed in the outcomes
  • Time frameNumber of participants with adverse events (AEs) and serious adverse events (SAEs)Approximatly 6 months → Approximatly 12 months
  • Time frameNumber of participants with clinical significant laboratory abnormalitiesApproximatly 6 months → Approximatly 12 months
Nov 13, 2026
Secondary outcomes
10 time frame changed, 1 added
What changed in the outcomes
  • AddedChange in hepatic fat contentTime frame: baseline, up to 12 months
  • Time framePeak plasma concentration (Cmax)Pre-dose, multiple timepoints post-dose up to Day 5 → Pre-dose, multiple timepoints post-dose up to D5
  • Time frameNumber and percentage of participants developing immunogenicity (anti-SA030 antibodies)Up to 6 months → Up to 12 months
  • Time frameChanges in weightbaseline, up to 24 weeks → baseline, up to 12 months
  • Time frameChanges in BMIbaseline, up to 24 weeks → baseline, up to 12 months
  • Time frameChanges in waist circumferencebaseline, up to 24 weeks → baseline, up to 12 months
  • Time frameChanges in hip circumference,baseline, up to 24 weeks → baseline, up to 12 months
  • Time frameChanges in waist-to-hip ratiobaseline, up to 24 weeks → baseline, up to 12 months
  • Time frameChanges in body fat contentbaseline, up to 24 weeks → baseline, up to 12 months
  • Time frameChanges in ALK7 expressionbaseline, up to 24 weeks → baseline, up to 12 months
  • Time frameChange in QTcF relative to baseline and relative to placebo compared to baselineFrom baseline to Day 13 → Pre-dose, multiple timepoints post-dose up to Day 5
Nov 13, 2026
Contact
Study contact changed: T•••@cmax.com.au · •••2715→z•••@siranbio.com · •••5926. See the current contact
Oct 23, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • Nucleus Network · Brisbane, AustraliaContact removed m•••@nucleusnetwork.com.au · •••2793
  • CMAX Clinical Research Pty Ltd North Terrace · Adelaide, AustraliaContact T•••@cmax.com.au · •••2715→none listedContact removed (no phone or email listed)
Nov 13, 2026
Title
A Study of SA030 Injection in Overweight/Obese Participants With or Obese ParticipantsWithout Type 2 Diabetes Mellitus (T2DM)
Nov 13, 2026
Show all 2 updates
  1. Nov 13, 2026
    Eligibility Maximum age 55 Years→65 Years
    Primary outcomes 2 time frame changed
    What changed in the outcomes
    • Time frameNumber of participants with adverse events (AEs) and serious adverse events (SAEs)Approximatly 6 months → Approximatly 12 months
    • Time frameNumber of participants with clinical significant laboratory abnormalitiesApproximatly 6 months → Approximatly 12 months
    Secondary outcomes 10 time frame changed, 1 added
    What changed in the outcomes
    • AddedChange in hepatic fat contentTime frame: baseline, up to 12 months
    • Time framePeak plasma concentration (Cmax)Pre-dose, multiple timepoints post-dose up to Day 5 → Pre-dose, multiple timepoints post-dose up to D5
    • Time frameNumber and percentage of participants developing immunogenicity (anti-SA030 antibodies)Up to 6 months → Up to 12 months
    • Time frameChanges in weightbaseline, up to 24 weeks → baseline, up to 12 months
    • Time frameChanges in BMIbaseline, up to 24 weeks → baseline, up to 12 months
    • Time frameChanges in waist circumferencebaseline, up to 24 weeks → baseline, up to 12 months
    • Time frameChanges in hip circumference,baseline, up to 24 weeks → baseline, up to 12 months
    • Time frameChanges in waist-to-hip ratiobaseline, up to 24 weeks → baseline, up to 12 months
    • Time frameChanges in body fat contentbaseline, up to 24 weeks → baseline, up to 12 months
    • Time frameChanges in ALK7 expressionbaseline, up to 24 weeks → baseline, up to 12 months
    • Time frameChange in QTcF relative to baseline and relative to placebo compared to baselineFrom baseline to Day 13 → Pre-dose, multiple timepoints post-dose up to Day 5
    Interventions Arm changed Dose escalation of SA030→Single dose escalation of SA030. Arms added: Multiple dose escalation of SA030 in obese participants·Multiple dose escalation of SA030 in obese with T2DM participants; arms removed: Matching placebo of SA030
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • Nucleus Network · Brisbane, AustraliaContact removed m•••@nucleusnetwork.com.au · •••2793
    • CMAX Clinical Research Pty Ltd North Terrace · Adelaide, AustraliaContact T•••@cmax.com.au · •••2715→none listedContact removed (no phone or email listed)
    Title A Study of SA030 Injection in Overweight/Obese Participants With or Obese ParticipantsWithout Type 2 Diabetes Mellitus (T2DM)
    + 3 other changes: index terms, description and conditions
  2. Oct 23, 2026
    Not yet recruiting→Recruiting
    1 site added. CMAX Clinical Research Pty Ltd North Terrace is now Recruiting
    Show site
    • Nucleus Network · Brisbane, Australia
    Primary completion Aug 18, 2026→Apr 24, 2028
    Study completion Mar 3, 2027→Apr 24, 2028
    Interventions Changed Dose escalation of SA030→SA030 Injection; Matching placebo of SA030→Matching Placebo
    Contact Study contact changed: T•••@cmax.com.au · •••2715→z•••@siranbio.com · •••5926. See the current contact

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07479862
Lead sponsor
Suzhou Siran Biotechnology Co.,Ltd.
Responsible party
Sponsor
First posted
Mar 18, 2026
Start date
Apr 16, 2026
Primary completion
Apr 24, 2028 (estimated)
Completion
Apr 24, 2028 (estimated)
Last update
Nov 13, 2026

Study contacts

Feifei Zhao
Contact
zhaofeifei@siranbio.com
86-051265295926

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion